UBS Group
ABEO icon

UBS Group’s Abeona Therapeutics ABEO Stock Holding History

UBS Group’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,000
Closed -$105K – 10405
2025
Q4 		$105K Buy
+20,000
New +$101K ﹤0.01% 6886

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OIA
OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group's ABEO Position: Q2 2026 in Review

UBS Group reduced its Abeona Therapeutics (ABEO) stake by 4.6% in Q2 2026, selling an estimated $58.4K and leaving 223,279 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #5442.

UBS Group first reported a position in ABEO in Q4 2015 and has held it in 34 quarters since. The position peaked at $2.18M in Q1 2018. 126 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

  • UBS Group held 223,279 shares of Abeona Therapeutics worth $1.38M as of Q2 2026.
  • UBS Group sold 10,645 Abeona Therapeutics shares in Q2 2026, an estimated $58.4K.
  • Abeona Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5442 holding.
  • UBS Group first reported a position in Abeona Therapeutics in Q4 2015 and has held it in 34 quarters since.
  • UBS Group's Abeona Therapeutics position peaked at $2.18M in Q1 2018.
  • 126 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.